Benzbromarone therapy in hyperuricaemia.
A series of patients with hyperuricaemia associated with rheumatic symptoms were treated with Benzbromarone (Minuric) and followed over a period of 5 months. Each patient was assessed clinically and biochemically before and at regular monthly intervals during the trial. All patients showed a marked reduction in serum uric acid levels and a significant increase in urinary uric acid elimination rates. Some degree of clinical improvement was noted in most patients and the drug was well tolerated throughout the study. Two patients were withdrawn during the trial; one because of diarrhoea, probably due to benzbromarone and the other because of lack of efficacy.
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001553:Benzbromarone / Q000627:therapeutic use*; D001572:Benzofurans / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014527:Uric Acid / Q000097:blood* / Q000652:urine
D001572:Benzofurans; D014527:Uric Acid; D001553:Benzbromarone; D003404:Creatinine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase